The University of Liverpool’s spin-out company, Galytx, has signed an exclusive licensing agreement with dermatology biotech Quodria. Together the companies plan to develop a first-in-class treatment for atopic dermatitis (AD), a form of eczema. Galytx, launched in June 2024, focuses on the development of galectin-3 targeted therapeutics for the treatment… Read More
Researchers from the University of Liverpool, UK, have created a biomedical compound that has the potential to stop the spread of breast cancer. Scientists from the Chemistry and Biochemistry Departments at the University of Liverpool and Nanjing Medical School in China have discovered a possible way… Read More
The Global Antibiotic Research and Development Partnership (GARDP) and the University of Liverpool have confirmed an agreement to collaborate on new projects to address antimicrobial resistance (AMR) for the benefit of public health. Since 2018, GARDP and the University of Liverpool have been working together to… Read More
